A Primer on Chimeric Antigen Receptor T-cell Therapy-related Toxicities for the Intensivist
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Primer on Chimeric Antigen Receptor T-cell Therapy-related Toxicities for the Intensivist
Authors
Keywords
-
Journal
JOURNAL OF INTENSIVE CARE MEDICINE
Volume -, Issue -, Pages -
Publisher
SAGE Publications
Online
2023-10-30
DOI
10.1177/08850666231205264
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dose fractionation of CAR-T cells. A systematic review of clinical outcomes
- (2023) Matthew Frigault et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)
- (2022) Marc Wehrli et al. Journal for ImmunoTherapy of Cancer
- The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
- (2022) Kai Rejeski et al. Journal for ImmunoTherapy of Cancer
- Anakinra utilization in refractory pediatric CAR T-cell associated toxicities
- (2022) Caroline Diorio et al. Blood Advances
- Long-Term Neurological Safety in B-Cell Lymphoma Patients Treated With Anti-CD19 CAR T-Cell Therapy
- (2022) Renata Ursu et al. NEUROLOGY
- The use of ICU resources in CAR-T cell recipients: a hospital-wide study
- (2022) Sandrine Valade et al. Annals of Intensive Care
- Interferon-γ blockade in CART-cell therapy-associated macrophage activation syndrome/hemophagocytic lymphohistiocytosis
- (2022) Michael Rainone et al. Blood Advances
- Continuous EEG monitoring detects nonconvulsive seizure and Ictal-Interictal Continuum abnormalities in moderate to severe ICANS following systemic CAR-T therapy
- (2022) Sammita Satyanarayan et al. Neurohospitalist
- Siltuximab for First-Line Treatment of Cytokine Release Syndrome: A Response to the National Shortage of Tocilizumab
- (2022) Seema Patel et al. BLOOD
- The CAR-Hematotox Score As a Prognostic Model of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma
- (2022) Kai Rejeski et al. BLOOD
- The CAR-Hematotox Score Identifies Patients at High Risk for Hematological Toxicity, Infections and Poor Clinical Outcomes Following Brexucabtagene Autoleucel in Relapsed/Refractory Mantle Cell Lymphoma
- (2022) Kai Rejeski et al. BLOOD
- Dose–response correlation for CAR-T cells: a systematic review of clinical studies
- (2022) Anand Rotte et al. Journal for ImmunoTherapy of Cancer
- Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma
- (2021) John H. Baird et al. Blood Advances
- Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study
- (2021) Élie Azoulay et al. Lancet Haematology
- CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma
- (2021) Kai Rejeski et al. BLOOD
- Characterization of HLH-Like Manifestations as a CRS Variant in Patients Receiving CD22 CAR T-Cells
- (2021) Daniel A Lichtenstein et al. BLOOD
- Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma
- (2021) Olalekan O. Oluwole et al. BRITISH JOURNAL OF HAEMATOLOGY
- Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity
- (2021) Cristina Gutierrez et al. CRITICAL CARE MEDICINE
- A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma
- (2021) Jae H Park et al. BLOOD
- Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma
- (2021) Max S. Topp et al. BRITISH JOURNAL OF HAEMATOLOGY
- Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline
- (2021) Bianca D. Santomasso et al. JOURNAL OF CLINICAL ONCOLOGY
- Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy
- (2021) Di Wang et al. Blood Cancer Journal
- Hypogammaglobulinemia After Chimeric Antigen Receptor (CAR) T-Cell Therapy: Characteristics, Management, and Future Directions
- (2021) Jeanette Wat et al. Journal of Allergy and Clinical Immunology-In Practice
- Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
- (2021) Ying Wang et al. Blood Advances
- Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma
- (2021) Vanessa E. Kennedy et al. Blood Advances
- Intrathecal Chemotherapy: An Alternative Treatment Strategy to Prolonged Corticosteroids for Severe CAR T Associated Neurotoxicity
- (2020) Filiz Yucebay et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
- (2020) Loretta J. Nastoupil et al. JOURNAL OF CLINICAL ONCOLOGY
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
- (2020) Michael Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP)
- (2020) Robert David Sandler et al. Frontiers in Immunology
- Toward Better Understanding and Management of CAR-T Cell–Associated Toxicity
- (2020) Andrea Schmidts et al. Annual Review of Medicine
- G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma
- (2020) Eugenio Galli et al. BONE MARROW TRANSPLANTATION
- Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma
- (2020) Kitsada Wudhikarn et al. Blood Cancer Journal
- DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality
- (2020) Kitsada Wudhikarn et al. Blood Advances
- Clinical efficacy of anakinra to mitigate CAR T-cell therapy–associated toxicity in large B-cell lymphoma
- (2020) Paolo Strati et al. Blood Advances
- Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies
- (2020) Tania Jain et al. Blood Advances
- Cardiovascular Events Associated with Chimeric Antigen Receptor T Cell Therapy: Cross-Sectional FDA Adverse Events Reporting System Analysis
- (2020) Avirup Guha et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- Ruxolitinib mitigates steroid‐refractory CRS during CAR T therapy
- (2020) Jing Pan et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
- (2020) Marcela V Maus et al. Journal for ImmunoTherapy of Cancer
- CAR T-cell associated neurotoxicity: Mechanisms, clinicopathologic correlates, and future directions
- (2019) Bradley D Hunter et al. JNCI-Journal of the National Cancer Institute
- Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T-cells
- (2019) Philipp Karschnia et al. BLOOD
- The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
- (2019) Katrin Mestermann et al. Science Translational Medicine
- CAR-T – and a side order of IgG, to go? – Immunoglobulin replacement in patients receiving CAR-T cell therapy
- (2019) Joshua A. Hill et al. BLOOD REVIEWS
- Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis
- (2019) Jingshi Wang et al. HAEMATOLOGICA
- Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
- (2018) Margherita Norelli et al. NATURE MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)
- (2018) Bianca D. Santomasso et al. Cancer Discovery
- Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
- (2018) Kris M. Mahadeo et al. Nature Reviews Clinical Oncology
- Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy
- (2018) Noelle Frey et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts
- (2018) Rosalie M. Sterner et al. BLOOD
- Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
- (2018) Juliane Gust et al. CNS DRUGS
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
- (2017) Sattva S. Neelapu et al. Nature Reviews Clinical Oncology
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
- (2016) D. T. Teachey et al. Cancer Discovery
- Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
- (2011) Antonio Di Stasi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy
- (2009) M. Griffioen et al. HAEMATOLOGICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started